NCT04103281 Expression Profiles of Integrin αDβ2 on Neutrophils in Sepsis
| NCT ID | NCT04103281 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Children's Hospital |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2020-09-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2020-09-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this research study we want to learn more about the characteristics of neutrophils that are present in the blood and secretions from a breathing tube of patients with sepsis. Sepsis is a severe type of infection, affecting various parts of the body. Neutrophils are a type of white blood cell that are part of the body's immune system. Even though neutrophils are important in getting rid of germs, they also may be harmful to parts of the body by causing injury in the lungs in patients with sepsis. Neutrophils can change their character in sepsis. Because of this, it is important for doctors to know what kind of neutrophils are in the blood and secretions from the breathing tube of patients with sepsis so that they can work to develop therapies to prevent these cells from being harmful.
Eligibility Criteria
Case Inclusion Criteria: * sepsis patient in the ICU with a breathing tube Control Inclusion Criteria: * scheduled for an elective surgical procedure and need preoperative blood draw or will have an intravenous catheter placed for the purpose of their surgical procedure * Plan to have endotracheal tube for planned procedures. Exclusion Criteria: * On chronic immunosuppressive drugs such as chronic corticosteroid use, or preexisting immunodeficiency diseases (oncology patients, patients with transplantation)
Contact & Investigator
Koichi Yuki, MD
PRINCIPAL INVESTIGATOR
Boston Children's Hospital
Frequently Asked Questions
Who can join the NCT04103281 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 50 Years, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04103281 currently recruiting?
Yes, NCT04103281 is actively recruiting participants. Contact the research team at koichi.yuki@childrens.harvard.edu for enrollment information.
Where is the NCT04103281 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT04103281 clinical trial?
NCT04103281 is sponsored by Boston Children's Hospital. The principal investigator is Koichi Yuki, MD at Boston Children's Hospital. The trial plans to enroll 75 participants.